Prevalence and Risk Factors for Adrenal Insufficiency in Patients with Multiple Myeloma Receiving Long-Term Chemotherapy including Corticosteroids: A Retrospective Cohort Study

Table 4

Clinical risk factors for adrenal insufficiency in patients with multiple myeloma.

	Univariate analysis			Multivariate analysis
	OR	95% CI		OR	95% CI
Age	1.03	0.99–1.05	0.077	1.03	0.99–1.06	0.121
Sex	1.09	0.68–1.74	0.716	0.98	0.56–1.65	0.946
Body mass index	1.03	0.97–1.10	0.332	1.05	0.98–1.12	0.210
Cumulative dose of corticosteroids^a	0.99	0.98–0.99	0.020	0.99	0.99–1.00	0.051
Cumulative duration of corticosteroid use	1.00	1.00–1.00	0.455	1.00	0.99–1.00	0.480
Cumulative dose/duration of corticosteroid use^a	1.00	0.99–1.00	0.802	1.01	1.00–1.00	0.269
Megestrol acetate use in the last regimen	2.63	1.48–4.67	0.001	2.54	1.41–4.60	0.002

OR: odds ratio; CI: confidence interval. ^aCorticosteroid doses were expressed in prednisolone equivalents.